Is Avenue Therapeutics, Inc. (ATXI) a Buy? The Stock Rises Again

March 14, 2018 - By Darrin Black

The stock of Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a huge mover today! The stock increased 14.32% or $0.68 during the last trading session, reaching $5.43. About 95,235 shares traded or 227.38% up from the average. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 5 months positive chart setup for the $55.74M company. It was reported on Mar, 14 by We have $5.65 PT which if reached, will make NASDAQ:ATXI worth $2.23M more.

More notable recent Avenue Therapeutics, Inc. (NASDAQ:ATXI) news were published by: which released: “Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial …” on January 02, 2018, also with their article: “Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President …” published on August 15, 2017, published: “Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO …” on February 06, 2018. More interesting news about Avenue Therapeutics, Inc. (NASDAQ:ATXI) were released by: and their article: “BRIEF-Avenue Therapeutics ic files for IPO of up to $50 mln” published on May 22, 2017 as well as‘s news article titled: “Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial …” with publication date: March 01, 2018.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $55.74 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.